Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
ABSTRACTThe field of immuno-oncology has revolutionized cancer patient care and improved survival and quality of life for patients. Much of the focus in the field has been on exploiting the power of the adaptive immune response through therapeutic targeting of T cells. While these approaches have ma...
Saved in:
Main Authors: | Kerry A. Whalen (Author), Kavya Rakhra (Author), Naveen K. Mehta (Author), Alexander Steinle (Author), Jennifer S. Michaelson (Author), Patrick A. Baeuerle (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
by: Bill Liao, et al.
Published: (2024) -
NKG2D (Natural Killer Group 2, Member D) ligand expression and ameloblastoma recurrence: a retrospective immunohistological pilot study
by: Mee-seon Kim, et al.
Published: (2024) -
Emerging Concepts on the NKG2D Receptor- NKG2D Ligand Axis in Health and Diseases
Published: (2020) -
Effect of Interleukin-15 on CD11b, CD54, and CD62L Expression on Natural Killer Cell and Natural Killer T-Like Cells in Systemic Lupus Erythematosus
by: Syh-Jae Lin, et al.
Published: (2016) -
NKG2D promotes CD8 T cell-mediated cytotoxicity and is associated with treatment failure in human cutaneous leishmaniasis.
by: Laís A Sacramento, et al.
Published: (2023)